| Vol. 5.36 – 1 October, 2021 |
| |
|
|
| Investigators established a metabolic phenotype that mediated radiation resistance in hepatocellular carcinoma (HCC), whereby increased glucose flux led to glucose addiction in radio-resistant HCC cells and a corresponding increase in glycerophospholipids biosynthesis to enhance the levels of cardiolipin. [Hepatology] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers showed that intrahepatic duct cells regenerated upon resumption of Jag/Notch signaling, from multipotent progenitors originating from an Fgf-dependent extrahepatic stem cell niche. [Hepatology] |
|
|
|
| The authors demonstrated that mice living in an enriched environment were protected from carcinogen-induced liver neoplasia and transplantable syngeneic liver tumors, owning to a CD8+ T cell-dependent tumor control. [Nature Communications] |
|
|
|
| The antitumor ability of corosolic acid (CA) was investigated by inhibiting the O-GlcNAcylation level and its corresponding mechanism. The results showed that high glucose (HG) could promote the proliferation of liver cancer cells, while CA could inhibit cell growth under HG conditions and tumor growth in a xenotransplantation model. [Cell Death & Disease] |
|
|
|
| High expression of circ_0011385 was observed in hepatocellular carcinoma tissues and cell lines and was significantly associated with tumor size, TNM stage, and prognosis. [Cell Death Discovery] |
|
|
|
| Scientists profiled 17,810 non-parenchymal cells derived from six healthy human livers, which enabled the identification of potential intercellular signaling axes and master regulators responsible for the activation of hepatic stellate cells during fibrogenesis. [Scientific Reports] |
|
|
|
| The anti-cancer effects of Tanshinone IIA (Tan-IIA) were investigated by using subcutaneous tumorigenic model in nude mice and in the human cholangiocarcinoma cell lines in vitro. Tan-IIA treatment considerably suppressed the proliferation and migration of Cholangiocarcinoma cells while inducing apoptosis of Cholangiocarcinoma cells. [Scientific Reports] |
|
|
|
| Researchers conducted quantitative reverse transcription PCR to find that circ_0004018 was down-regulated in hepatocellular carcinoma cells. Western blot analysis was performed to detect the protein levels of phosphatase and tensin homologue and related factors of PI3K/AKT signaling pathway. [Cell Cycle] |
|
|
|
| The lncRNA, mRNA and miRNA levels in hepatocellular carcinoma (HCC) tissues or cells were measured using real-time quantitative polymerase chain reaction. Results showed that LncRNA LOC107985656 was downregulated in HCC tissues and cells. [Bioengineered] |
|
|
|
| Scientists showed that Enterococcus faecalis was abundant in the microbiota of patients with hepatitis C virus-related chronic liver disease. Xenotransplantation of gut microbiota from these patients increased the number of spontaneous liver tumors in mice and enhanced susceptibility to liver carcinogens. [Nature Cancer] |
|
|
|
|
| The authors offer a comprehensive overview of pathophysiological and clinical aspects of autoimmune hepatitis. [Cellular & Molecular Immunology] |
|
|
|
| Scientists cover the recent advancements in the identification of proteomic/genomic/epigenomic/transcriptomic biomarkers for predicting hepatocellular carcinoma treatment efficacy with the use of multi-kinase inhibitors, CDK4/6 inhibitors, and immune checkpoint inhibitors. [Expert Review of Molecular Diagnostics] |
|
|
|
|
| Enochian BioSciences, Inc. announced the completion of a Pre-Investigational New Drug process for ENOB-HB-01, a novel approach to potentially eliminate HBV-infected liver cells with an innovative “Hijack RNA” strategy that co-opts the virus’ machinery to induce the death of infected cells rather than reproducing and causing more infection and liver disease. [Enochian BioSciences, Inc.] |
|
|
|
| Lion TCR Pte Ltd announced that it has received clearance from US FDA for its Investigational New Drug Application for LioCyx-M004, autologous T-cells transfected with mRNA encoding Hepatitis B surface antigen specific TCR. [Lion TCR Pte Ltd] |
|
|
|
|
| October 5 – 6, 2021 Virtual |
|
|
|
|
|
| University of Cambridge – Cambridge, England, United Kingdom |
|
|
|
| The University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| Herman B Wells Center for Pediatric Research – Indianapolis, Indiana, United States |
|
|
|
| St. Jude Children’s Research Hospital – Memphis, Tennessee, United States |
|
|
|
| European Centre Study Diabetes – Strasbourg, France |
|
|
|
|